Yao L - Search Results

1

Signal-induced enhancer activation requires Ku70 to read topoisomerase1-DNA covalent complexes.

Tan Y, Yao L, Gamliel A, Nair SJ, Taylor H, Ohgi K, Aggarwal AK, Rosenfeld MG. Tan Y, et al. Among authors: yao l. Nat Struct Mol Biol. 2023 Feb;30(2):148-158. doi: 10.1038/s41594-022-00883-8. Epub 2023 Feb 6. Nat Struct Mol Biol. 2023. PMID: 36747093 Free PMC article.

2

Cancer risk in relatives of BRCA1/2 pathogenic variant carriers in a large series of unselected patients with breast cancer.

Liu J, Yao L, Sun J, Hu L, Chen J, Zhang J, Xu Y, Xie Y. Liu J, et al. Among authors: yao l. Cancer Biol Med. 2023 Mar 2;20(2):147-54. doi: 10.20892/j.issn.2095-3941.2022.0593. Cancer Biol Med. 2023. PMID: 36861435 Free PMC article.

3

Association between 15 known or potential breast cancer susceptibility genes and breast cancer risks in Chinese women.

Fu F, Zhang D, Hu L, Sundaram S, Ying D, Zhang Y, Fu S, Zhang J, Yao L, Xu Y, Xie Y. Fu F, et al. Among authors: yao l. Cancer Biol Med. 2021 Oct 5;19(2):253-62. doi: 10.20892/j.issn.2095-3941.2021.0358. Online ahead of print. Cancer Biol Med. 2021. PMID: 34606182 Free PMC article.

4

Impact of multifocal or multicentric disease on local recurrence and survival in breast cancer patients with or without BRCA1/2 variants.

Liu X, Wang Y, Cao K, Yao L, Hu L, Sun J, Zhang J, Xu Y, Xie Y. Liu X, et al. Among authors: yao l. Breast Cancer Res Treat. 2023 May;199(1):25-33. doi: 10.1007/s10549-023-06904-4. Epub 2023 Mar 17. Breast Cancer Res Treat. 2023. PMID: 36930346

5

Predicting the likelihood of BRCA1/2 germline pathogenic variants in unselected patients with breast cancer: analysis of more than 10,000 individuals.

Sun J, Yao L, Chen J, Hu L, Zhang J, Xu Y, Xie Y. Sun J, et al. Among authors: yao l. J Med Genet. 2024 Dec 11:jmg-2024-110332. doi: 10.1136/jmg-2024-110332. Online ahead of print. J Med Genet. 2024. PMID: 39663109

6

Characteristics of Chinese breast cancer patients with double heterozygosity for BRCA1 and BRCA2 germline pathogenic variants.

Wen S, Zhang M, Chen J, Hu L, Sun J, Yao L, Xu Y, Zhang J, Xie Y. Wen S, et al. Among authors: yao l. Breast Cancer Res Treat. 2024 Nov;208(1):155-164. doi: 10.1007/s10549-024-07409-4. Epub 2024 Jun 20. Breast Cancer Res Treat. 2024. PMID: 38900213

7

BRCA-CRisk: A Contralateral Breast Cancer Risk Prediction Model for BRCA Carriers.

Sun J, Chu F, Pan J, Zhang Y, Yao L, Chen J, Hu L, Zhang J, Xu Y, Wang X, Cao W, Xie Y. Sun J, et al. Among authors: yao l. J Clin Oncol. 2023 Feb 10;41(5):991-999. doi: 10.1200/JCO.22.00833. Epub 2022 Dec 8. J Clin Oncol. 2023. PMID: 36480783

8

Ovarian cancer risk of Chinese women with BRCA1/2 germline pathogenic variants.

Yao L, Sun J, Hu L, Chen J, Zhang J, Xu Y, Xie Y. Yao L, et al. J Hum Genet. 2022 Nov;67(11):639-642. doi: 10.1038/s10038-022-01065-6. Epub 2022 Jul 21. J Hum Genet. 2022. PMID: 35864222

9

Low Expression of PALB2 is Associated With Poor Survival in Chinese Women With Primary Breast Cancer.

Liu J, Chen J, Sun J, Yao L, Zhang J, Xie Y, Xu Y. Liu J, et al. Among authors: yao l. Clin Breast Cancer. 2023 Jun;23(4):e259-e266. doi: 10.1016/j.clbc.2023.03.003. Epub 2023 Mar 8. Clin Breast Cancer. 2023. PMID: 36997402

10

BRCA1 c.5470_5477del, a founder mutation in Chinese Han breast cancer patients.

Meng H, Yao L, Yuan H, Xu Y, Ouyang T, Li J, Wang T, Fan Z, Fan T, Lin B, Xie Y. Meng H, et al. Among authors: yao l. Int J Cancer. 2020 Jun 1;146(11):3044-3052. doi: 10.1002/ijc.32877. Epub 2020 Feb 22. Int J Cancer. 2020. PMID: 31957001

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

8,882 results

Search Page

Filters